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Abstract
Background
Premature discontinuation of clinical studies affects about 25% of randomised controlled tri-
als (RCTs) which raises concerns about waste of scarce resources for research. The risk of
discontinuation of non-randomised prospective studies (NPSs) is yet unclear.
Objectives
To compare the proportion of discontinued studies between NPSs and RCTs that received
ethical approval.
Methods
We systematically surveyed prospective longitudinal clinical studies that were approved by
a single REC in Freiburg, Germany between 2000 and 2002. We collected study character-
istics, identified subsequent publications, and surveyed investigators to elucidate whether
a study was discontinued and, if so, why.
Results
Of 917 approved studies, 547 were prospective longitudinal studies (306 RCTs and 241
NPSs). NPSs were on average smaller than RCTs, more frequently single centre and pilot
studies, and less frequently funded by industry. NPSs were less frequently discontinued
than RCTs: 32/221 (14%) versus 78/288 (27%, p<0.001, missing data excluded). Poor
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recruitment was the most frequent reason for discontinuation in both NPSs (36%) and
RCTs (37%).
Conclusions
Compared to RCTs, NPSs were at lower risk for discontinuation. Measures to reliably pre-
dict, sustain, and stimulate recruitment could prevent discontinuation of many RCTs but
also of some NPSs.
Introduction
In recent years, many methodological investigations and guidance documents about rando-
mised controlled trials (RCTs) have been published, whereas problems in the planning and
conduct of other prospective clinical studies such as non-randomised controlled trials, single
arm trials or cohort studies (non-randomised prospective studies, NPSs) are less well known.
A major reason for failure of RCTs is premature discontinuation; about one quarter of
planned RCTs are prematurely discontinued, mostly due to recruitment problems [1–5]. Dis-
continuation is rarely reported to research ethics committees (RECs) and about half of discon-
tinued RCTs remain unpublished [1, 3]. This is a serious ethical concern for volunteering
participants and the society at large as it represents a waste of scarce resources, a loss of valu-
able research data, and missed opportunities to learn from failure [1, 2, 6].
Similar ethical implications would apply to NPSs. However, their premature discontinua-
tion has not been investigated in depth so far. (Retrospective or cross-sectional studies are not
discussed in this paper because the mechanisms for discontinuation differ from prospective
studies. For instance, they cannot be discontinued for slow benefit, harm, futility, or slow
recruitment). It is unknownwhether the risk and reasons for discontinuation of NPSs differ
from RCTs. Pilot or feasibility NPSs conducted on selected populations may be less prone to
discontinuation due to poor recruitment than confirmative RCTs that need to achieve a certain
sample size to establish the effectiveness of a treatment. A study on a sample of cardiovascular
trials registered in ClinicalTrials.gov showed that besides funding by federal agencies and beha-
vioural therapies, a single arm study design is associated with a lower risk of early termination
due to poor recruitment [7]. Furthermore, studies suggest that it is easier to recruit participants
into NPSs [8, 9]. On the other hand, NPSs may be more frequently explorative in nature
including first-in-human studies or early pharmacological studies [7]. Those studies are typi-
cally surrounded by more uncertainties concerning the potential benefit and harms an inter-
vention could have for patients, and may thus bear a higher risk for discontinuation.
The aim of this analysis was to study the discontinuation of clinical studies that were
approved by a REC, and to compare the prevalence of and reasons for discontinuation between
NPSs and RCTs.
Methods
We had access to all study protocols submitted to the REC of the University of Freiburg / Ger-
many from 2000 to 2002, including RCTs and NPS [10, 11]. If a study protocol described two
or more studies, we considered each study separately.
We included studies that 1) enrolled patients or healthy volunteers (hereafter referred to as
‘participants’), 2) collected baseline data after initiation of the study (prospective studies), and
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3) had at least one follow-up time point regardless of time elapsed since baseline (longitudinal
studies).We excluded retrospective longitudinal and cross-sectional studies because our main
outcome “discontinuation of recruitment and/or follow-up” would not apply. Furthermore, we
excluded studies if we certainly knew that they were never started or were still on-going at time
of data collection (Fig 1). We considered a study on-going if investigators indicated this in
response to our survey and if results had not been published.
We used the following definitions to classify NPSs (Fig 1):
1. Controlled trial: Participants are systematically assigned to two or more parallel exposure
(intervention) group defining the study arms. An exposure (intervention) could be in one
time point or repeated / continued over a defined period of time.
2. Single arm trial: All participants are assigned to one exposure (intervention) group.
3. Cohort study: Participants are not actively assigned to exposure groups; those are defined
by observed characteristics or exposures.
Details of data collection have been describedpreviously [10, 11]. REC files included local
application forms, the study protocols with amendments and correspondencewith the REC.
We extracted information about study centre status (multicentre international/national, single
centre), sample size, pilot study, medical field, inclusion criteria, and source of funding (indus-
try/non-industry).We considered a study industry-sponsored if the protocol clearly named the
sponsor, displayed a company or institution logo prominently, mentioned affiliations of proto-
col authors, or included statements about data ownership or publication rights, or statements
about full funding by industry or public funding agencies. If only some study material (e.g. the
Fig 1. Algorithm for classifying study designs.
doi:10.1371/journal.pone.0165605.g001
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experimental drug) was provided by a private company and academic investigators wrote the
study protocol, we did not consider the study industry-sponsored.
We used pre-piloted standardized forms for all extracted information and provided detailed
written data extraction instructions. To minimize extraction errors, we conducted formal cali-
bration exercises with all data extractors and extracted 30% of the RCTs in duplicate. NPSs
data were extracted by one investigator (PO). All database entries were checked for plausibility
and about one third of the data was cross-checked by a second investigator (AB), so that we are
confident that we achieved a high level of accuracy. If the investigator in charge could not
decide on how to extract data (e.g. when classifying studies by design), the issue was discussed
with a second investigator. If data extraction still remained unclear, a third investigator (SS)
was involved to reach consensus.
In a second step, we established a specific search strategy for each study protocol using rele-
vant keywords from the protocol such as experimental drug, study name or acronym, studied
disease or condition or names of applicants. We searched the databases Medline, Web of Sci-
ence, publication registry of the University of Freiburg, via Medpilot the databases of Current
Contents Medizin, the publishers Hogrefe, Karger, Kluwer, Springer and Thieme, and Google
Scholar. For RCTs we also searched the CochraneCentral Register of Controlled Trials (CEN-
TRAL) of the Cochrane Library. When we calculated the proportion of published studies, we
considered only articles published in peer-reviewed journals; in contrast to conference
abstracts and grey literature, peer reviewed journal articles are indexed in electronic databases
and can be identified reliably. Estimates of publication proportions based on peer-reviewed
articles are therefore more reliable but also more relevant. Literature searches were conducted
in 2011/2012 for study protocols of the year 2000 and in 2009/2010 for those of the years 2001
and 2002, and in 2014 for all RCTs.
We contacted the applicants of all included protocols by a personalised letter including a
questionnaire to confirm the publications identified by us and to ask for additional publica-
tions (S1 Appendix). We also asked about premature discontinuation and the reason(s)
thereof. The survey of investigators was conducted in 2007 for protocols of the year 2000, in
2010 for protocols of the years 2001 and 2002, and in 2013 for all RCTs. The survey response
rate in Freiburg was 90.0% for RCTs and non-RCTs. We grouped the reasons for study discon-
tinuation provided by the investigators into the following categories: poor recruitment, benefit,
harm, futility, lack of funding or other reasons (including administrative reasons such as retire-
ment or change of institute of principal investigator or disagreement with sponsor).
Our primary analysis was to compare the proportion of discontinued studies betweenNPSs
and RCTs. We calculated proportions based on complete cases (excluding studies with missing
status information) and conducted sensitivity analyses assuming that a) unclear/missing stud-
ies were completed, b) unclear/missing studies were discontinued, or c) half of unclear/missing
studies were discontinued. The latter assumption that unclear/missing studies were more likely
to be discontinued was based on the observation that unknown status was associated with non-
publication which is known to be associated with discontinuation [1]. In another sensitivity
analysis, we excluded studies stopped for harm, benefit, or futility. The rationale was to enable
a ‘fairer’ comparison because cohort studies cannot be stopped for these reasons. We used the
chi-square test to test for differences in proportions (based on the assumption that studies
approved in Freiburg are a random sample of studies approved in comparable jurisdictions
and future studies) and a type I error of 5% as threshold for statistical significance.
To explore potential differences across countries and jurisdictions,we compared the study
characteristics and discontinuation between the RCTs approved in Freiburg and RCTs
approved in Canada (Hamilton) and Switzerland (Basel, Lausanne, Zurich, and Lucerne) at the
same time period.Details about this cohort of 1017 RCTs were reported earlier [1, 12].
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Results
Included studies
We identified 917 studies that were approved by the REC in Freiburg (Fig 2). After excluding
studies that were never started, still on-going, in vitro or other non-human studies, or of cross-
sectional or retrospective design, our final data set for analysis comprised 547 prospective lon-
gitudinal studies. Of those, 306 were RCTs and 241 were NPSs (27 controlled trials, 158 single
arm trials, and 56 cohort studies).
Study characteristics
Most NPSs (92%) and RCTs (92%) were conducted in adults. NPSs were on average smaller
than RCTs, more frequently single centre and pilot studies, and less frequently industry-spon-
sored (Table 1). Most NPSs and RCTs were in oncology (20%; 22%) and neurology (11%; 9%).
NPSs were less often conducted in cardiovascularmedicine (3%; 9%) and more often in dental
medicine (6%; 2%). Fourty-nine precent of NPSs were published compared to 59% of RCTs.
Study discontinuation
Overall, NPSs were less frequently discontinued than RCTs (14% versus 27%, missing
excluded, p<0.001) (Tables 2 and 3). Sensitivity analyses using different assumption for
Fig 2. Study selection.
doi:10.1371/journal.pone.0165605.g002
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missing data only slightly changed these proportions and the differences betweenNPSs and
RCTs. In the sensitivity analysis excluding studies stopped for harm, benefit, or futility the dif-
ference betweenNPSs and RCTs was no longer statistically significant (p = 0.057, missing
excluded, see Table 3). Poor recruitment was the most frequent reason for discontinuation in
both NPSs (37%) and RCTs (36%) (Table 2). Completion status was very similar in RCTs
approved in Freiburg and in Canada or Switzerland.
Table 1. Study characteristics.
Study characteristics REC Freiburg Other RECs1
Controlled trial Single arm trial Cohort study Total NPSs RCTs RCTs
Total n 27 (100) 158 (100) 56 (100) 241 (100) 306 (100) 711 (100)
Sample size provided 27 (100) 154 (97) 54 (96) 235 (98) 302 (99) 697 (98)
Median; IQR 30; 20–48 60; 30–238 115;50–300 60; 30–230 200; 81–449 240; 60–600
Centre status
Single centre 25 (93) 46 (29) 37 (66) 108 (45) 70 (23) 191 (27)
Multi centre—national 1 (4) 45 (29) 13 (23) 59 (25) 67 (22) 92 (13)
Multi centre—international 1 (4) 66 (42) 6 (11) 73 (30) 155 (51) 404 (57)
Unclear/missing 0 1 (1) 0 1 (<1) 14 (5) 24 (3)
Labelled as pilot study 14 (52) 34 (22) 19 (34) 67 (28) 36 (12) 47 (7)
Sponsorship
Industry2 9 (33) 99 (63) 10 (18) 118 (49) 182 (59) 455 (64)
Non-industry 18 (67) 59 (37) 46 (82) 123 (51) 124 (41) 256 (36)
Medical field
Oncology 3 (11) 40 (25) 7 (12) 50 (21) 66 (22) 90 (13)
Cardiovascular 0 (0) 5 (3) 3 (5) 8 (3) 27 (9) 90 (13)
Infectious disease 2 (7) 12 (8) 5 (9) 19 (8) 23 (8) 78 (11)
Endocrinology 1 (4) 3 (2) 1 (2) 5 (2) 14 (5) 64 (9)
Neurology 3 (11) 18 (11) 8 (14) 29 (12) 27 (9) 39 (5)
Gastroenterology 0 1 (1) 1 (2) 2 (1) 12 (4) 52 (7)
Respiratory 0 4 (3) 3 (5) 7 (2) 15 (5) 46 (6)
Psychiatry 3 (11) 15 (9) 4 (7) 22 (9) 20 (7) 25 (4)
Dermatology 4 (15) 8 (5) 2 (4) 14 (6) 21 (7) 16 (2)
Haematology 0 9 (6) 2 (4) 11 (5) 9 (3) 27 (4)
Dental / facial surgery 7 (16) 6 (4) 1 (2) 14 (6) 5 (2) 1 (0)
Other 4 (15) 37 (23) 19 (34) 60 (25) 67 (22) 183 (26)
Age group
Adult 26 (96) 148 (94) 47 (84) 221 (92) 283 (92) 648 (91)
Paediatric 1 (4) 10 (6) 9 (16) 20 (8) 23 (8) 63 (9)
Participants
Patients 18 (67) 142 (90) 45 (80) 205 (85) 282 (92) 612 (86)
Healthy volunteers 8 (30) 11 (7) 3 (5) 22 (9) 24 (8) 99 (14)
Both 1 (4) 5 (3) 8 (14) 14 (6) 0 0
Published in peer-reviewed journal 15 (56) 74 (47) 29 (52) 118 (49) 180 (59) 387 (54)
1 approved by 5 research ethics committees in Switzerland and Canada [1].
2 includes 37 RCTs and 13 non-RCTs with industry funding but no industry involvement, i. e. in study planning, management or analysis of data.
All percentages (in brackets) refer to the total number of the respective column
Abbreviations: NPSs, non-randomised prospective studies; RCTs, randomised controlled trials; IQR, interquartile range.
doi:10.1371/journal.pone.0165605.t001
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Table 2. Study status, reasons for discontinuation.
Study characteristics REC Freiburg Other RECs1
Controlled trial Single arm trial Cohort study Total NPSs RCTs RCTs
Total n 27 158 56 241 306 711
Study status
Completed2 23 124 42 189 210 474
Unclear/missing2 2 10 8 20 18 62
Discontinued2 2 24 6 32 78 175
Reasons for discontinuation
Poor recruitment 1 (50%) 6 (27%) 4 (67%) 11 (37%) 28 (36%) 73 (42%)
Withdrawal by sponsor/ lack of funding 0 5 (23%) 0 5 (17%) 3 (4%) 2 (1%)
Benefit 0 0 0 0 6 (8%) 3 (2%)
Harm 1 (50%) 2 (95%) 0 3 (10%) 7 (9%) 17 (10%)
Futility 0 3 (14%) 0 3 (10%) 16 (21%) 21 (12%)
Other reasons3 0 6 (27%) 2 (33%) 8 (27%) 17 (22%) 35 (20%)
Unclear/missing 0 2 0 2 1 24
1 approved by 5 research ethics committees in Switzerland and Canada [1].
The numbers in brackets are proportions (column %) based on complete cases (excluding unclear/missing)
2 Please see Table 3 for proportions
3 Other reasons: administrative; retirement; change of institute of applicant; lack of staff resources; lack of flexibility of the system; logistical problems, i.e.
interdisciplinary study organisation and logistics; number of participants too small; studies conducted by other researcher were larger and more meaningful;
pilot phase failed, test material was insufficient; study data were deleted during maintenance works by the technician; change of study design; change of
topic; termination of the liver transplant programme at the University Medical Center Freiburg by the government; shifting of the research focus of the study
investigator
Abbreviations: NPSs, non-randomised prospective studies; RCTs, randomised controlled trials.
doi:10.1371/journal.pone.0165605.t002
Table 3. Proportion of discontinued trials.
REC Freiburg Other
RECs1
Controlled
trial
Single arm
trial
Cohort
study
Total
NPSs
RCTs Comparison total NPS vs
RCTs P
RCTs
All studies
Unclear/missing = excluded 8% 16% 13% 14% 27% <0.001 27%
Unclear/missing = completed 7% 15% 11% 13% 25% <0.001 25%
Unclear/missing = discontinued 15% 22% 25% 22% 31% 0.014 33%
Unclear/missing = 50% completed, 50%
discontinued
11% 18% 18% 17% 28% 0.004 29%
Excluding studies stopped for harm, benefit, futility
Unclear/missing = excluded 4% 13% 13% 12% 19% 0.057 22%
Unclear/missing = completed 4% 12% 11% 11% 18% 0.047 20%
Unclear/missing = discontinued 12% 19% 25% 20% 24% 0.251 29%
Unclear/missing = 50% completed, 50%
discontinued
8% 16% 18% 15% 21% 0.128 25%
1 approved by 5 research ethics committees in Switzerland and Canada [1].
Estimated proportion of discontinued studies applying different assumptions for missing data with or without excluding studies that were stopped for
intervention-related reasons such as harm, benefit, and futility (see text for a rationale).
Abbreviations: NPSs, non-randomised prospective studies; RCTs, randomised controlled trials.
doi:10.1371/journal.pone.0165605.t003
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Discussion
We compared the risk of discontinuation betweenNPSs and RCTs in a sample of clinical stud-
ies approved by a German REC.
Overall, NPSs were at lower risk of discontinuation than RCTs (14% versus 27%, p<0.001).
The difference was robust to sensitivity analyses using different assumptions for missing data,
however, when we excluded studies stopped for harm, benefit, or futility, the difference in the
proportion of discontinued studies diminished and was no longer significant. This is obviously
due to the fact that cohort studies are not being stopped for harm, benefit, or futility.
A strength of our study is that we had access to the full REC correspondence from a period
of three years. Consequently, we could take into account relevant information from the appli-
cation form, the study protocol with its amendments, patient information sheets and additional
correspondence. In addition, we achieved a high response rate in our survey. The included
RCTs were remarkably similar to RCTs that were approved at the same time by five RECs in
Switzerland and Canada. This increases our confidence that the findings will be generalizable
to clinical research settings in other high-income countries.
A main limitation of our study was that for some studies only little information was avail-
able, e.g. due to missing or poor reporting in study documents.When a study protocol was
missing, we extracted relevant information from application forms and patient information
sheets.While all RCTs conducted in the jurisdiction of the REC needed to obtain ethical
approval, the regulations were less strict for NPSs between the years 2000 and 2002. We could
not quantify the number of NPSs that were never assessed by the REC. Consequently, it is pos-
sible that our sample of NPSs overrepresented more challenging studies for which ethical
approval was deemed critical and that it might not be representative of NPSs in general. Finally,
when we applied statistical tests and formulated our conclusions, we implicitly regarded the
studies approved in Freiburg as being representative of other clinical studies approved in other
jurisdictions. This assumption is supported by the fact that characteristics of RCT in Freiburg
were very similar to characteristics of RCTs in Switzerland and Canada (Table 1). However,
results may differ among studies performed in jurisdictionswhere unique challenges exist,
such as developing countries.
Only few previous studies have reported on the risk of discontinuation in NPSs. We
screened two systematic reviews including methodological studies on studies approved by
RECs or included in trial registries [13, 14]. One study followed a cohort of 367 studies (137
RCTs and 230 studies of other designs) approved by a single REC in Oxford, UK, between
1984 and 1987 [15]. It did not investigate differences between study designs due to the low
number of discontinued studies. Similar to our study, poor recruitment was the main reason
for study discontinuation across designs. Compared to completed studies, discontinued studies
were more likely to be non-comparative (33% vs 27%) and single centre (83% vs 76%). Another
study was based on cardiovascular studies registered in ClinicalTrials.gov [7]. Again, slow
recruitment was the main reason for study discontinuation. In addition, single arm design was
independently associated with lower risk for recruitment failure. Our sample did not include
enough single arm trials to explore this potential association.
Conclusions
Our analysis suggests that NPSs may be at lower risk for discontinuation than RCTs. Poor
recruitment was the main reason for study discontinuation in both RCTs and NPSs. Measures
to reliably predict, stimulate and sustain recruitment performancemay prevent the discontinu-
ation of many NPSs and RCTs in the future [16–18].
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